Rapid Testing for Sexually Transmitted Infections in Pregnancy

This trial examines whether a quick test can help detect and treat syphilis and HIV earlier in pregnant patients. It evaluates the effectiveness of the Chembio HIV/Syphilis rapid Point of Care (POC) test alongside standard lab tests in the emergency room. Pregnant individuals visiting the emergency department who have received limited prenatal care or testing for HIV or syphilis during their current pregnancy may qualify for this trial.

As an unphased trial, this study provides a unique opportunity to contribute to important research that could enhance early detection and treatment for others.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Chembio HIV/Syphilis rapid test is generally safe to use. For HIV, the test correctly identifies 99.8% of people with the disease and 98.4% of those without it. For syphilis, it correctly identifies 98.8% of people with the disease and 99.4% of those without it. These high numbers indicate that the test is reliable and well-tolerated. Studies have found that testing for both HIV and syphilis simultaneously is cost-effective and helps reduce pregnancy-related issues. Overall, the evidence supports this rapid test as a safe choice for pregnant women.¹²³⁴⁵

Unlike the standard of care for detecting HIV and syphilis during pregnancy, which typically relies on lab-based testing, the Chembio HIV/Syphilis rapid Point of Care (POC) test offers a unique advantage with its quick, on-the-spot results. This rapid test allows for immediate diagnosis, potentially reducing the time to treatment and improving outcomes for both mothers and their babies. Researchers are excited about this test because it simplifies the testing process, making it more accessible and efficient, especially in settings where laboratory resources are limited.

Research has shown that the Chembio HIV/Syphilis rapid Point of Care (POC) test effectively detects HIV and syphilis. One study found that this test correctly identifies HIV 99.8% of the time and syphilis 98.8% of the time, meaning it almost always detects these infections. The test also accurately avoids false positives, rarely indicating an infection when there isn't one. In this trial, participants will receive the Chembio HIV/Syphilis rapid POC test alongside standard lab-based HIV/Syphilis testing. Testing for both HIV and syphilis simultaneously is more cost-effective and helps prevent more pregnancy complications than testing for each separately. Overall, this quick test can serve as a reliable first step in screening pregnant women for these infections.¹²³⁴⁶